Luecht, U.R.; Scholz, W.; Geiben, A.-K.; Haen, E.; Hempel, G.
Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion—The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm. Pharmaceutics 2025, 17, 179.
https://doi.org/10.3390/pharmaceutics17020179
AMA Style
Luecht UR, Scholz W, Geiben A-K, Haen E, Hempel G.
Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion—The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm. Pharmaceutics. 2025; 17(2):179.
https://doi.org/10.3390/pharmaceutics17020179
Chicago/Turabian Style
Luecht, Ulrich Ruben, Wolfgang Scholz, Ann-Kathrin Geiben, Ekkehard Haen, and Georg Hempel.
2025. "Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion—The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm" Pharmaceutics 17, no. 2: 179.
https://doi.org/10.3390/pharmaceutics17020179
APA Style
Luecht, U. R., Scholz, W., Geiben, A.-K., Haen, E., & Hempel, G.
(2025). Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion—The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm. Pharmaceutics, 17(2), 179.
https://doi.org/10.3390/pharmaceutics17020179
